Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) Guideline update 2025

Main Recommendations

At a population level, the European Society of Gastrointestinal Endoscopy (ESGE), the European Helicobacter and Microbiota Study Group (EHMSG), and the European Society of Pathology (ESP) suggest endoscopic screening for gastric cancer (and precancerous conditions) in high-risk regions (age-standardized rate [ASR] > 20 per 100 000 person-years) every 2 to 3 years or, if cost–effectiveness has been proven, in intermediate risk regions (ASR 10–20 per 100 000 person-years) every 5 years, but not in low-risk regions (ASR < 10).

ESGE/EHMSG/ESP recommend that irrespective of country of origin, individual gastric risk assessment and stratification of precancerous conditions is recommended for first-time gastroscopy.

ESGE/EHMSG/ESP suggest that gastric cancer screening or surveillance in asymptomatic individuals over 80 should be discontinued or not started, and that patients’ comorbidities should be considered when treatment of superficial lesions is planned.

ESGE/EHMSG/ESP recommend that a high quality endoscopy including the use of virtual chromoendoscopy (VCE), after proper training, is performed for screening, diagnosis, and staging of precancerous conditions (atrophy and intestinal metaplasia) and lesions (dysplasia or cancer), as well as after endoscopic therapy. VCE should be used to guide the sampling site for biopsies in the case of suspected neoplastic lesions as well as to guide biopsies for diagnosis and staging of gastric precancerous conditions, with random biopsies to be taken in the absence of endoscopically suspected changes. When there is a suspected early gastric neoplastic lesion, it should be properly described (location, size, Paris classification, vascular and mucosal pattern), photodocumented, and two targeted biopsies taken.

ESGE/EHMSG/ESP do not recommend routine performance of endoscopic ultrasonography (EUS), computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT prior to endoscopic resection unless there are signs of deep submucosal invasion or if the lesion is not considered suitable for endoscopic resection.

ESGE/EHMSG/ESP recommend endoscopic submucosal dissection (ESD) for differentiated gastric lesions clinically staged as dysplastic (low grade and high grade) or as intramucosal carcinoma (of any size if not ulcerated or ≤ 30 mm if ulcerated), with EMR being an alternative for Paris 0-IIa lesions of size ≤ 10 mm with low likelihood of malignancy.

ESGE/EHMSG/ESP suggest that a decision about ESD can be considered for malignant lesions clinically staged as having minimal submucosal invasion if differentiated and ≤ 30 mm; or for malignant lesions clinically staged as intramucosal, undifferentiated and ≤ 20 mm; and in both cases with no ulcerative findings.

ESGE/EHMSG/ESP recommends patient management based on the following histological risk after endoscopic resection:

Curative/very low-risk resection (lymph node metastasis [LNM] risk < 0.5 %–1 %): en bloc R0 resection; dysplastic/pT1a, differentiated lesion, no lymphovascular invasion, independent of size if no ulceration and ≤ 30 mm if ulcerated. No further staging procedure or treatment is recommended.

Curative/low-risk resection (LNM risk < 3 %): en bloc R0 resection; lesion with no lymphovascular invasion and: a) pT1b, invasion ≤ 500 µm, differentiated, size ≤ 30 mm; or b) pT1a, undifferentiated, size ≤ 20 mm and no ulceration. Staging should be completed, and further treatment is generally not necessary, but a multidisciplinary discussion is required.

Local-risk resection (very low risk of LNM but increased risk of local persistence/recurrence): Piecemeal resection or tumor-positive horizontal margin of a lesion otherwise meeting curative/very low-risk criteria (or meeting low-risk criteria provided that there is no submucosal invasive tumor at the resection margin in the case of piecemeal resection or tumor-positive horizontal margin for pT1b lesions [invasion ≤ 500 µm; well-differentiated; size ≤ 30 mm, and VM0]). Endoscopic surveillance/re-treatment is recommended rather than other additional treatment.

High-risk resection (noncurative): Any lesion with any of the following: (a) a positive vertical margin (if carcinoma) or lymphovascular invasion or deep submucosal invasion (> 500 µm from the muscularis mucosae); (b) poorly differentiated lesions if ulceration or size > 20 mm; (c) pT1b differentiated lesions with submucosal invasion ≤ 500 µm with size > 30 mm; or (d) intramucosal ulcerative lesion with size > 30 mm. Complete staging and strong consideration for additional treatments (surgery) in multidisciplinary discussion.

ESGE/EHMSG/ESP suggest the use of validated endoscopic classifications of atrophy (e. g. Kimura–Takemoto) or intestinal metaplasia (e. g. endoscopic grading of gastric intestinal metaplasia [EGGIM]) to endoscopically stage precancerous conditions and stratify the risk for gastric cancer.

ESGE/EHMSG/ESP recommend that biopsies should be taken from at least two topographic sites (2 biopsies from the antrum/incisura and 2 from the corpus, guided by VCE) in two separate, clearly labeled vials. Additional biopsy from the incisura is optional.

ESGE/EHMSG/ESP recommend that patients with extensive endoscopic changes (Kimura C3 + or EGGIM 5 +) or advanced histological stages of atrophic gastritis (severe atrophic changes or intestinal metaplasia, or changes in both antrum and corpus, operative link on gastritis assessment/operative link on gastric intestinal metaplasia [OLGA/OLGIM] III/IV) should be followed up with high quality endoscopy every 3 years, irrespective of the individual’s country of origin.

ESGE/EHMSG/ESP recommend that no surveillance is proposed for patients with mild to moderate atrophy or intestinal metaplasia restricted to the antrum, in the absence of endoscopic signs of extensive lesions or other risk factors (family history, incomplete intestinal metaplasia, persistent H. pylori infection). This group constitutes most individuals found in clinical practice.

ESGE/EHMSG/ESP recommend H. pylori eradication for patients with precancerous conditions and after endoscopic or surgical therapy.

ESGE/EHMSG/ESP recommend that patients should be advised to stop smoking and low-dose daily aspirin use may be considered for the prevention of gastric cancer in selected individuals with high risk for cardiovascular events.

• References

• 1 The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol 2020; 5: 42-54
• 2 Rugge M, Genta RM, Malfertheiner P. et al. RE. GA.IN.: the Real-world Gastritis Initiative – updating the updates. . Gut 2024; 73: 407-441
• 3 Rodríguez de Santiago E, Dinis-Ribeiro M, Pohl H. et al. Reducing the environmental footprint of gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Position Statement. Endoscopy 2022; 54: 797-826
• 4 Dinis-Ribeiro M, Areia M, de Vries AC. et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012; 44: 74-94
• 5 Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T. et al. Endoscopic submucosal dissection: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 47: 829-54
• 6 Dinis-Ribeiro M, Shah S, El-Serag H. et al. The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines. Gut 2024; 73: 1607-1617
• 7 Weusten B, Bisschops R, Dinis-Ribeiro M. et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2023; 55: 1124-46
• 8 AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 2003; 12: 18-23
• 9 Pimentel-Nunes P, Libânio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365-88
• 10 Pimentel-Nunes P, Libânio D, Bastiaansen BAJ. et al. Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2022. Endoscopy 2022; 54: 591-622
• 11 Atkins D, Eccles M, Flottorp S. et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004; 4: 38
• 12 Guyatt GH, Oxman AD, Vist GE. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-926
• 13 Blair VR, McLeod M, Carneiro F. et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020; 21: e386-e397
• 14 Lordick F, Carneiro F, Cascinu S. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1005-1020
• 15 Libânio D, Pimentel-Nunes P, Bastiaansen B. et al. Endoscopic submucosal dissection techniques and technology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Review. Endoscopy 2023; 55: 361-389
• 16 Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy 2005; 37: 570-578
• 17 Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan 1968; 59: 251-258
• 18 Mariette C, Carneiro F, Grabsch HI. et al. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer 2019; 22: 1-9
• 19 Digestive system tumours. WHO Classification of Tumours. Lokuhetty D, White V, Watanabe R. et al. Lyon: IARC; 2019
• 20 Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma [in Japanese]. Tokyo: Kanehara; 2017
• 21 Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. . Acta Pathol Microbiol Scand 1965; 64: 31-49
• 22 Zhang X, Li M, Chen S. et al. Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality: a meta-analysis and systematic review. Gastroenterology 2018; 155: 347-354.e9
• 23 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328.e7
• 24 Januszewicz W, Turkot MH, Malfertheiner P. et al. A global perspective on gastric cancer screening: which concepts are feasible, and when?. Cancers (Basel) 2023; 15: 664
• 25 Areia M, Carvalho R, Cadime AT. et al. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter 2013; 18: 325-337
• 26 Huang HL, Leung CY, Saito E. et al. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Med 2020; 18: 257
• 27 Săftoiu A, Hassan C, Areia M. et al. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020; 52: 293-304
• 28 Areia M, Spaander MC, Kuipers EJ. et al. Endoscopic screening for gastric cancer: A cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J 2018; 6: 192-202
• 29 Libanio D, Antonelli G, Marijnissen F. et al. Combined gastric and colorectal cancer endoscopic screening may be cost-effective in Europe with the implementation of artificial intelligence: an economic evaluation. Eur J Gastroenterol Hepatol 2024; 36: 155-161
• 30 Banks M, Graham D, Jansen M. et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019; 68: 1545-1575
• 31 Malfertheiner P, Megraud F, Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022;
• 32 Saumoy M, Schneider Y, Shen N. et al. Cost effectiveness of gastric cancer screening according to race and ethnicity. Gastroenterology 2018; 155: 648-660
• 33 Shah SC, Canakis A, Peek RM. et al. Endoscopy for gastric cancer screening is cost effective for asian americans in the United States. Clin Gastroenterol Hepatol 2020; 18: 3026-3039
• 34 Weck MN, Brenner H. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers Prev 2006; 15: 1083-1094
• 35 Yin Y, Liang H, Wei N. et al. Prevalence of chronic atrophic gastritis worldwide from 2010 to 2020: an updated systematic review and meta-analysis. Ann Palliat Med 2022; 11: 3697-3703
• 36 Li Y, Jiang F, Wu CY. et al. Prevalence and temporal trend of gastric preneoplastic lesions in Asia: A systematic review with meta-analysis. United European Gastroenterol J 2024; 12: 139-151
• 37 Marques-Silva L, Areia M, Elvas L. et al. Prevalence of gastric precancerous conditions: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2014; 26: 378-387
• 38 Areia M, Dinis-Ribeiro M, Rocha Gonçalves F. Cost-utility analysis of endoscopic surveillance of patients with gastric premalignant conditions. Helicobacter 2014; 19: 425-436
• 39 Omidvari AH, Meester RG, Lansdorp-Vogelaar I. Cost effectiveness of surveillance for GI cancers. Best Pract Res Clin Gastroenterol 2016; 30: 879-891
• 40 Thiruvengadam NR, Gupta S, Buller S. et al. The clinical impact and cost-effectiveness of surveillance of incidentally detected gastric intestinal metaplasia: a microsimulation analysis. Clin Gastroenterol Hepatol 2024; 22: 51-61
• 41 Ligato I, Dottori L, Sbarigia C. et al. Systematic review and meta-analysis: Risk of gastric cancer in patients with first-degree relatives with gastric cancer. Aliment Pharmacol Ther 2024; 59: 606-615
• 42 Yaghoobi M, McNabb-Baltar J, Bijarchi R. et al. What is the quantitative risk of gastric cancer in the first-degree relatives of patients? A meta-analysis.. World J Gastroenterol 2017; 23: 2435-2342
• 43 He G, Ji X, Yan Y. et al. Which individuals with positive family history of gastric cancer urgently need intensive screening and eradication of Helicobacter pylori? systematic review and meta-analysis.. Iran J Public Health 2021; 50: 2384-2396
• 44 Vitelli-Storelli F, Rubín-García M, Pelucchi C. et al. Family history and gastric cancer risk: a pooled investigation in the Stomach Cancer Pooling (STOP) Project Consortium. Cancers (Basel) 2021; 13: 3844
• 45 Rodríguez-de-Santiago E, Frazzoni L, Fuccio L. et al. Digestive findings that do not require endoscopic surveillance – Reducing the burden of care: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020; 52: 491-497
• 46 Cubiella J, Pérez Aisa Á, Cuatrecasas M. et al. Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP. Gastroenterol Hepatol 2021; 44: 67-86
• 47 Lin XK, Wang WL. Analysis of high risk factors for chronic atrophic gastritis. Saudi J Gastroenterol 2023; 29: 127-134
• 48 Sivandzadeh GR, Zadeh Fard SA, Zahmatkesh A. et al. Value of serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection. Middle East J Dig Dis 2023; 15: 37-44
• 49 Chapelle N, Osmola M, Martin J. et al. Serum pepsinogens combined with new biomarkers testing using chemiluminescent enzyme immunoassay for non-invasive diagnosis of atrophic gastritis: a prospective, multicenter study. Diagnostics 2022; 12: 695
• 50 Nguyen CL, Dao TT, Phi TN. et al. Serum pepsinogen: A potential non-invasive screening method for moderate and severe atrophic gastritis among an Asian population. Ann Med Surg (Lond) 2022; 78: 103844
• 51 Huang RJ, Park S, Shen J. et al. Pepsinogens and gastrin demonstrate low discrimination for gastric precancerous lesions in a multi-ethnic united states cohort. Clin Gastroenterol Hepatol 2022; 20: 950-952.e3
• 52 Miftahussurur M, Waskito LA, Syam AF. et al. Serum pepsinogen level as a biomarker for atrophy, reflux esophagitis, and gastric cancer screening in Indonesia. J Res Med Sci 2022; 27: 90
• 53 Ogutmen Koc D, Bektas S. Serum pepsinogen levels and OLGA/OLGIM staging in the assessment of atrophic gastritis types. Postgrad Med J 2022; 98: 441-445
• 54 Cai HL, Tong YL. Association of serum pepsinogen with degree of gastric mucosal atrophy in an asymptomatic population. World J Clin Cases 2021; 9: 9431-9439
• 55 Chapelle N, Petryszyn P, Blin J. et al. A panel of stomach-specific biomarkers (GastroPanel®) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area. Helicobacter 2020; 25: e12727
• 56 Whary MT, Avenia JMR, Bravo LE. et al. Contrasting serum biomarker profiles in two Colombian populations with different risks for progression of premalignant gastric lesions during chronic Helicobacter pylori infection. Cancer Epidemiol 2020; 67: 101726
• 57 Miftahussurur M, Waskito LA, Aftab H. et al. Serum pepsinogens as a gastric cancer and gastritis biomarker in South and Southeast Asian populations. PLoS One 2020; 15: e0230064
• 58 Zeng W, Zhang S, Yang L. et al. Serum miR-101–3p combined with pepsinogen contributes to the early diagnosis of gastric cancer. BMC Med Genet 2020; 21: 28
• 59 Wang Y, Liu X, Wang L. et al. A comparative study on changes in intestinal flora, pepsinogen and gastrin in patients with gastric cancer and atrophic gastritis. J BUON 2020; 25: 995-1000
• 60 Mezmale L, Isajevs S, Bogdanova I. et al. Prevalence of atrophic gastritis in Kazakhstan and the accuracy of pepsinogen tests to detect gastric mucosal atrophy. Asian Pac J Cancer Prev 2019; 20: 3825-3829
• 61 Dondov G, Amarbayasgalan D, Batsaikhan B. et al. Diagnostic performances of pepsinogens and gastrin-17 for atrophic gastritis and gastric cancer in Mongolian subjects. PLoS One 2022; 17: e0274938
• 62 Chiang TH, Maeda M, Yamada H. et al. Risk stratification for gastric cancer after Helicobacter pylori eradication: A population-based study on Matsu Islands. J Gastroenterol Hepatol 2021; 36: 671-679
• 63 Bang CS, Lee JJ, Baik GH. Prediction of chronic atrophic gastritis and gastric neoplasms by serum pepsinogen assay: a systematic review and meta-analysis of diagnostic test accuracy. J Clin Med 2019; 8: 657
• 64 Syrjänen K. Accuracy of serum biomarker panel (GastroPanel(®)) in the diagnosis of atrophic gastritis of the corpus. systematic review and meta-analysis.. Anticancer Res 2022; 42: 1679-1696
• 65 Januszewicz W, Witczak K, Wieszczy P. et al. Prevalence and risk factors of upper gastrointestinal cancers missed during endoscopy: a nationwide registry-based study. Endoscopy 2022; 54: 653-660
• 66 Pimenta-Melo AR, Monteiro-Soares M, Libânio D. et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2016; 28: 1041-1049
• 67 Kamran U, Abbasi A, Umar N. et al. Umbrella systematic review of potential quality indicators for the detection of dysplasia and cancer at upper gastrointestinal endoscopy. Endosc Int Open 2023; 11: E835-E848
• 68 Kawamura T, Wada H, Sakiyama N. et al. Examination time as a quality indicator of screening upper gastrointestinal endoscopy for asymptomatic examinees. Dig Endosc 2017; 29: 569-575
• 69 Park JM, Huo SM, Lee HH. et al. Longer observation time increases proportion of neoplasms detected by esophagogastroduodenoscopy. Gastroenterology 2017; 153: 460-469.e1
• 70 Teh JL, Tan JR, Lau LJ. et al. Longer examination time improves detection of gastric cancer during diagnostic upper gastrointestinal endoscopy. Clin Gastroenterol Hepatol 2015; 13: 480-487.e2
• 71 Yoshimizu S, Hirasawa T, Horiuchi Y. et al. Differences in upper gastrointestinal neoplasm detection rates based on inspection time and esophagogastroduodenoscopy training. Endosc Int Open 2018; 6: E1190-E1197
• 72 Park JM, Kim SY, Shin GY. et al. Implementation effect of institutional policy of EGD observation time on neoplasm detection. Gastrointest Endosc 2021; 93: 1152-1159
• 73 Romańczyk M, Romańczyk T, Lesińska M. et al. The relation of esophagogastroduodenoscopy time and novel upper gastrointestinal quality measures. Eur J Gastroenterol Hepatol 2022; 34: 763-768
• 74 Gao Y, Cai MX, Tian B. et al. Setting 6-minute minimal examination time improves the detection of focal upper gastrointestinal tract lesions during endoscopy: a multicenter prospective study. Clin Transl Gastroenterol 2023; 14: e00612
• 75 Kim HY. Clinical features of gastric adenoma detected within 3 years after negative screening endoscopy in Korea. Gastroenterol Rep (Oxf) 2023; 11: goad039
• 76 Kim SY, Park JM, Cho HS. et al. Assessment of cimetropium bromide use for the detection of gastric neoplasms during esophagogastroduodenoscopy. JAMA Netw Open 2022; 5: e223827
• 77 Ishibashi F, Kobayashi K, Fukushima K. et al. Quality indicators for the detection of helicobacter pylori-negative early gastric cancer: a retrospective observational study. Clin Endosc 2020; 53: 698-704
• 78 Kim TJ, Pyo JH, Byun YH. et al. Interval advanced gastric cancer after negative endoscopy. Clin Gastroenterol Hepatol 2023; 21: 1205-1213.e2
• 79 Burke E, Harkins P, Moriarty F. et al. Does premedication with mucolytic agents improve mucosal visualization during oesophagogastroduodenoscopy: a systematic review and meta-analysis. Surg Res Pract 2021;
• 80 Sajid MS, Rehman S, Chedgy F. et al. Improving the mucosal visualization at gastroscopy: a systematic review and meta-analysis of randomized, controlled trials reporting the role of simethicone ± N-acetylcysteine. Transl Gastroenterol Hepatol 2018; 3: 29
• 81 Li Y, Du F, Fu D. The effect of using simethicone with or without N-acetylcysteine before gastroscopy: A meta-analysis and systemic review. Saudi J Gastroenterol 2019; 25: 218-228
• 82 Zhang LY, Li WY, Ji M. et al. Efficacy and safety of using premedication with simethicone/Pronase during upper gastrointestinal endoscopy examination with sedation: A single center, prospective, single blinded, randomized controlled trial. Dig Endosc 2018; 30: 57-64
• 83 Liu X, Guan CT, Xue LY. et al. Effect of premedication on lesion detection rate and visualization of the mucosa during upper gastrointestinal endoscopy: a multicenter large sample randomized controlled double-blind study. Surg Endosc 2018; 32: 3548-3556
• 84 Manfredi G, Bertè R, Iiritano E. et al. Premedication with simethicone and N-acetylcysteine for improving mucosal visibility during upper gastrointestinal endoscopy in a Western population. Endosc Int Open 2021; 9: E190-E194
• 85 Romańczyk M, Ostrowski B, Kozłowska-Petriczko K. et al. Scoring system assessing mucosal visibility of upper gastrointestinal tract: The POLPREP scale. J Gastroenterol Hepatol 2022; 37: 164-168
• 86 Khan R, Gimpaya N, Vargas JI. et al. The Toronto Upper Gastrointestinal Cleaning Score: a prospective validation study. Endoscopy 2023; 55: 121-128
• 87 Córdova H, Barreiro-Alonso E, Castillo-Regalado E. et al. Applicability of the Barcelona scale to assess the quality of cleanliness of mucosa at esophagogastroduodenoscopy. Gastroenterol Hepatol 2024; 47: 246-252
• 88 Romańczyk M, Ostrowski B, Lesińska M. et al. The prospective validation of a scoring system to assess mucosal cleanliness during EGD. Gastrointest Endosc 2024; 100: 27-35
• 89 Zhang Q, Chen ZY, Chen CD. et al. Training in early gastric cancer diagnosis improves the detection rate of early gastric cancer: an observational study in China. Medicine (Baltimore) 2015; 94: e384
• 90 Wang Q, Zhang SY, Wu X. et al. Feasibility of standardized procedures of white light gastroscopy for clinical practice: A multicenter study in China. J Dig Dis 2021; 22: 656-662
• 91 Di L, Wu H, Zhu R. et al. Multi-disciplinary team for early gastric cancer diagnosis improves the detection rate of early gastric cancer. BMC Gastroenterol 2017; 17: 147
• 92 Manfredi G, Pedaci M, Iiritano E. et al. Impact of improved upper endoscopy quality on detection of gastric precancerous lesions. Eur J Gastroenterol Hepatol 2023; 35: 285-287
• 93 Le H, Wang L, Zhang L. et al. Magnifying endoscopy in detecting early gastric cancer: A network meta-analysis of prospective studies. Medicine (Baltimore) 2021; 100: e23934
• 94 Lu JH, Chen HH, Chen X. et al. Evaluation of the detection rate of high grade gastric intraepithelial neoplasia using linked color imaging and white light imaging. Exp Ther Med 2023; 25: 107
• 95 Higashino M, Ono S, Matsumoto S. et al. Improvement of detection sensitivity of upper gastrointestinal epithelial neoplasia in linked color imaging based on data of eye tracking. J Gastroenterol Hepatol 2023; 38: 710-715
• 96 Gao J, Zhang X, Meng Q. et al. Linked color imaging can improve detection rate of early gastric cancer in a high-risk population: a multi-center randomized controlled clinical trial. Dig Dis Sci 2021; 66: 1212-129
• 97 Min M, Sun X, Bai J. et al. Diagnostic accuracy of linked colour imaging versus white light imaging for early gastric cancers: a prospective, multicentre, randomized controlled trial study. Ann Med 2022; 54: 3306-3314
• 98 Rokkas T, Ekmektzoglou K. Current role of narrow band imaging in diagnosing gastric intestinal metaplasia: a systematic review and meta-analysis of its diagnostic accuracy. Ann Gastroenterol 2023; 36: 149-156
• 99 Rodriguez-Carrasco M, Esposito G, Libanio D. et al. Image-enhanced endoscopy for gastric preneoplastic conditions and neoplastic lesions: a systematic review and meta-analysis. Endoscopy 2020; 52: 1048-1065
• 100 Shu X, Wu G, Zhang Y. et al. Diagnostic value of linked color imaging based on endoscopy for gastric intestinal metaplasia: a systematic review and meta-analysis. Ann Transl Med 2021; 9: 506
• 101 Desai M, Boregowda U, Srinivasan S. et al. Narrow band imaging for detection of gastric intestinal metaplasia and dysplasia: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021; 36: 2038-2046
• 102 Sobrino-Cossio S, Teramoto-Matsubara O, Emura F. et al. Usefulness of optical enhancement endoscopy combined with magnification to improve detection of intestinal metaplasia in the stomach. Endosc Int Open 2022; 10: E441-E447
• 103 Wu CCH, Namasivayam V, Li JW. et al. A prospective randomized tandem gastroscopy pilot study of linked color imaging versus white light imaging for detection of upper gastrointestinal lesions. J Gastroenterol Hepatol 2021; 36: 2562-2567
• 104 Buxbaum JL, Hormozdi D, Dinis-Ribeiro M. et al. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. Gastrointest Endosc 2017; 86: 857-865
• 105 Lage J, Pimentel-Nunes P, Figueiredo PC. et al. Light-NBI to identify high-risk phenotypes for gastric adenocarcinoma: do we still need biopsies?. Scand J Gastroenterol 2016; 51: 501-506
• 106 Ji R, Liu J, Zhang MM. et al. Optical enhancement imaging versus acetic acid for detecting gastric intestinal metaplasia: A randomized, comparative trial. Dig Liver Dis 2020; 52: 651-657
• 107 Faknak N, Pittayanon R, Tiankanon K. et al. Performance status of targeted biopsy alone versus Sydney protocol by non-NBI expert gastroenterologist in gastric intestinal metaplasia diagnosis. Endosc Int Open 2022; 10: E273-E279
• 108 Dekker E, Houwen B, Puig I. et al. Curriculum for optical diagnosis training in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020; 52: 899-923
• 109 Yao K, Anagnostopoulos GK, Ragunath K. Magnifying endoscopy for diagnosing and delineating early gastric cancer. Endoscopy 2009; 41: 462-467
• 110 Yoshifuku Y, Sanomura Y, Oka S. et al. Clinical usefulness of the VS classification system using magnifying endoscopy with blue laser imaging for early gastric cancer. Gastroenterol Res Pract 2017; 2017: 3649705
• 111 Pimentel-Nunes P, Dinis-Ribeiro M, Soares JB. et al. A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. Endoscopy 2012; 44: 236-246
• 112 Mabe K, Yao K, Nojima M. et al. An educational intervention to improve the endoscopist's ability to correctly diagnose small gastric lesions using magnifying endoscopy with narrow-band imaging. Ann Gastroenterol 2014; 27: 149-155
• 113 Nakanishi H, Doyama H, Ishikawa H. et al. Evaluation of an e-learning system for diagnosis of gastric lesions using magnifying narrow-band imaging: a multicenter randomized controlled study. Endoscopy 2017; 49: 957-967
• 114 Dias-Silva D, Pimentel-Nunes P, Magalhães J. et al. The learning curve for narrow-band imaging in the diagnosis of precancerous gastric lesions by using Web-based video. Gastrointest Endosc 2014; 79: 910-920 ; quiz 83.e1, 83.e4
• 115 Yao K, Uedo N, Muto M. et al. Development of an e-learning system for the endoscopic diagnosis of early gastric cancer: an international multicenter randomized controlled trial. EBioMedicine 2016; 9: 140-147
• 116 Tiankanon K, Pittayanon R, Faknak N. et al. Diagnostic validity and learning curve of non-NBI expert endoscopists in gastric intestinal metaplasia diagnosis. Surg Endosc 2023; 37: 6771-6778
• 117 Omura H, Yoshida N, Hayashi T. et al. Interobserver agreement in detection of "white globe appearance" and the ability of educational lectures to improve the diagnosis of gastric lesions. Gastric Cancer 2017; 20: 620-628
• 118 Quek SXZ, Lee JWJ, Feng Z. et al. Comparing artificial intelligence to humans for endoscopic diagnosis of gastric neoplasia: An external validation study. J Gastroenterol Hepatol 2023; 38: 1587-1591
• 119 Feng J, Yu SR, Zhang YP. et al. A system based on deep convolutional neural network improves the detection of early gastric cancer. Front Oncol 2022; 12: 1021625
• 120 Jin J, Zhang Q, Dong B. et al. Automatic detection of early gastric cancer in endoscopy based on Mask region-based convolutional neural networks (Mask R-CNN)(with video). Front Oncol 2022; 12: 927868
• 121 Zhou B, Rao X, Xing H. et al. A convolutional neural network-based system for detecting early gastric cancer in white-light endoscopy. Scand J Gastroenterol 2023; 58: 157-162
• 122 Yao Z, Jin T, Mao B. et al. Construction and multicenter diagnostic verification of intelligent recognition system for endoscopic images from early gastric cancer based on YOLO-V3 algorithm. Front Oncol 2022; 12: 815951
• 123 Oura H, Matsumura T, Fujie M. et al. Development and evaluation of a double-check support system using artificial intelligence in endoscopic screening for gastric cancer. Gastric Cancer 2022; 25: 392-400
• 124 Wu L, Xu M, Jiang X. et al. Real-time artificial intelligence for detecting focal lesions and diagnosing neoplasms of the stomach by white-light endoscopy (with videos). Gastrointest Endosc 2022; 95: 269-280.e6
• 125 Nam JY, Chung HJ, Choi KS. et al. Deep learning model for diagnosing gastric mucosal lesions using endoscopic images: development, validation, and method comparison. Gastrointest Endosc 2022; 95: 258-268.e10
• 126 Wu L, He X, Liu M. et al. Evaluation of the effects of an artificial intelligence system on endoscopy quality and preliminary testing of its performance in detecting early gastric cancer: a randomized controlled trial. Endoscopy 2021; 53: 1199-1207
• 127 Tang D, Wang L, Ling T. et al. Development and validation of a real-time artificial intelligence-assisted system for detecting early gastric cancer: A multicentre retrospective diagnostic study. EBioMedicine 2020; 62: 103146
• 128 Luo H, Xu G, Li C. et al. Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study. Lancet Oncol 2019; 20: 1645-1654
• 129 Horiuchi Y, Aoyama K, Tokai Y. et al. Convolutional neural network for differentiating gastric cancer from gastritis using magnified endoscopy with narrow band imaging. Dig Dis Sci 2020; 65: 1355-1363
• 130 Ikenoyama Y, Hirasawa T, Ishioka M. et al. Detecting early gastric cancer: Comparison between the diagnostic ability of convolutional neural networks and endoscopists. Dig Endosc 2021; 33: 141-150
• 131 Hirasawa T, Aoyama K, Tanimoto T. et al. Application of artificial intelligence using a convolutional neural network for detecting gastric cancer in endoscopic images. Gastric Cancer 2018; 21: 653-660
• 132 Ueyama H, Kato Y, Akazawa Y. et al. Application of artificial intelligence using a convolutional neural network for diagnosis of early gastric cancer based on magnifying endoscopy with narrow-band imaging. J Gastroenterol Hepatol 2021; 36: 482-489
• 133 Liu L, Dong Z, Cheng J. et al. Diagnosis and segmentation effect of the ME-NBI-based deep learning model on gastric neoplasms in patients with suspected superficial lesions - a multicenter study. Front Oncol 2022; 12: 1075578
• 134 Luo D, Kuang F, Du J. et al. Artificial intelligence-assisted endoscopic diagnosis of early upper gastrointestinal cancer: a systematic review and meta-analysis. Front Oncol 2022; 12: 855175
• 135 Ma M, Li Z, Yu T. et al. Application of deep learning in the real-time diagnosis of gastric lesion based on magnifying optical enhancement videos. Front Oncol 2022; 12: 945904
• 136 Chen PC, Lu YR, Kang YN. et al. The accuracy of artificial intelligence in the endoscopic diagnosis of early gastric cancer: pooled analysis study. J Med Internet Res 2022; 24: e27694
• 137 Jiang K, Jiang X, Pan J. et al. Current evidence and future perspective of accuracy of artificial intelligence application for early gastric cancer diagnosis with endoscopy: a systematic and meta-analysis. Front Med (Lausanne) 2021; 8: 629080
• 138 Tang D, Ni M, Zheng C. et al. A deep learning-based model improves diagnosis of early gastric cancer under narrow band imaging endoscopy. Surg Endosc 2022; 36: 7800-7810
• 139 Yoon HJ, Kim S, Kim JH. et al. A lesion-based convolutional neural network improves endoscopic detection and depth prediction of early gastric cancer. J Clin Med 2019; 8(9).
• 140 Arribas J, Antonelli G, Frazzoni L. et al. Standalone performance of artificial intelligence for upper GI neoplasia: a meta-analysis. Gut 2020;
• 141 Wu L, Shang R, Sharma P. et al. Effect of a deep learning-based system on the miss rate of gastric neoplasms during upper gastrointestinal endoscopy: a single-centre, tandem, randomised controlled trial. Lancet Gastroenterol Hepatol 2021; 6: 700-708
• 142 Zhang Y, Li F, Yuan F. et al. Diagnosing chronic atrophic gastritis by gastroscopy using artificial intelligence. Dig Liver Dis 2020; 52: 566-572
• 143 Zhao Q, Chi T. Deep learning model can improve the diagnosis rate of endoscopic chronic atrophic gastritis: a prospective cohort study. BMC Gastroenterol 2022; 22: 133
• 144 Luo J, Cao S, Ding N. et al. A deep learning method to assist with chronic atrophic gastritis diagnosis using white light images. Dig Liver Dis 2022; 54: 1513-1519
• 145 Zhao Q, Jia Q, Chi T. Deep learning as a novel method for endoscopic diagnosis of chronic atrophic gastritis: a prospective nested case-control study. BMC Gastroenterol 2022; 22: 352
• 146 Kodaka Y, Futagami S, Watanabe Y. et al. Determination of gastric atrophy with artificial intelligence compared to the assessments of the modified Kyoto and OLGA classifications. JGH Open 2022; 6: 704-10
• 147 Zhao Q, Jia Q, Chi T. U-Net deep learning model for endoscopic diagnosis of chronic atrophic gastritis and operative link for gastritis assessment staging: a prospective nested case-control study. Therap Adv Gastroenterol 2023;
• 148 Xu M, Zhou W, Wu L. et al. Artificial intelligence in the diagnosis of gastric precancerous conditions by image-enhanced endoscopy: a multicenter, diagnostic study (with video). Gastrointest Endosc 2021; 94: 540-548.e4
• 149 Tao X, Zhu Y, Dong Z. et al. An artificial intelligence system for chronic atrophic gastritis diagnosis and risk stratification under white light endoscopy. Dig Liver Dis 2024; 56: 1319-1326
• 150 Shi Y, Wei N, Wang K. et al. Diagnostic value of artificial intelligence-assisted endoscopy for chronic atrophic gastritis: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10: 1134980
• 151 Dilaghi E, Lahner E, Annibale B. et al. Systematic review and meta-analysis: Artificial intelligence for the diagnosis of gastric precancerous lesions and Helicobacter pylori infection. Dig Liver Dis 2022; 54: 1630-1638
• 152 Guimarães P, Keller A, Fehlmann T. et al. Deep-learning based detection of gastric precancerous conditions. Gut 2020; 69: 4-6
• 153 Messmann H, Bisschops R, Antonelli G. et al. Expected value of artificial intelligence in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2022; 54: 1211-1231
• 154 Kanesaka T, Nagahama T, Uedo N. et al. Clinical predictors of histologic type of gastric cancer. Gastrointest Endosc 2018; 87: 1014-1022
• 155 Kim Y, Yoon HJ, Kim JH. et al. Effect of histologic differences between biopsy and final resection on treatment outcomes in early gastric cancer. Surg Endosc 2020; 34: 5046-5054
• 156 Jeon SW, Park HW, Kwon YH. et al. Endoscopic indication of endoscopic submucosal dissection for early gastric cancer is not compatible with pathologic criteria in clinical practice. Dig Dis Sci 2019; 64: 373-381
• 157 Pouw RE, Barret M, Biermann K. et al. Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. European Society of Gastrointestinal Endoscopy (ESGE) Guideline.. Endoscopy 2021; 53: 1174-1188
• 158 Nishitani M, Yoshida N, Tsuji S. et al. Optimal number of endoscopic biopsies for diagnosis of early gastric cancer. Endosc Int Open 2019; 7: E1683-e90
• 159 Han KS, Sohn DK, Choi DH. et al. Prolongation of the period between biopsy and EMR can influence the nonlifting sign in endoscopically resectable colorectal cancers. Gastrointest Endosc 2008; 67: 97-102
• 160 De Marco MO, Tustumi F, Brunaldi VO. et al. Prognostic factors for ESD of early gastric cancers: a systematic review and meta-analysis. Endosc Int Open 2020; 8: E1144-e55
• 161 Lee SH, Kim MC, Jeon SW. et al. Risk factors and clinical outcomes of non-curative resection in patients with early gastric cancer treated with endoscopic submucosal dissection: a retrospective multicenter study in Korea. Clin Endosc 2020; 53: 196-205
• 162 Han SY, Yoon HJ, Kim JH. et al. Nomogram for pre-procedural prediction of non-curative endoscopic resection in patients with early gastric cancer. Surg Endosc 2023; 37: 4594-4603
• 163 Ma X, Zhang Q, Zhu S. et al. Risk factors and prediction model for non-curative resection of early gastric cancer with endoscopic resection and the evaluation. Front Med (Lausanne) 2021; 8: 637875
• 164 Tang YH, Ren LL, Yu YN. et al. Systemic immune-inflammation index in predicting non-curative resection of endoscopic submucosal dissection in patients with early gastric cancer. Eur J Gastroenterol Hepatol 2023; 35: 376-383
• 165 Embaye KS, Zhang C, Ghebrehiwet MA. et al. Clinico-pathologic determinants of non-e-curative outcome following en-bloc endoscopic submucosal dissection in patients with early gastric neoplasia. BMC Cancer 2021; 21: 92
• 166 Figueiroa G, Pimentel-Nunes P, Dinis-Ribeiro M. et al. Gastric endoscopic submucosal dissection: a systematic review and meta-analysis on risk factors for poor short-term outcomes. Eur J Gastroenterol Hepatol 2019; 31: 1234-1246
• 167 Kim TS, Min BH, Kim KM. et al. Risk-scoring system for prediction of non-curative endoscopic submucosal dissection requiring additional gastrectomy in patients with early gastric cancer. J Gastric Cancer 2021; 21: 368-378
• 168 Kim EH, Park JC, Song IJ. et al. Prediction model for non-curative resection of endoscopic submucosal dissection in patients with early gastric cancer. Gastrointest Endosc 2017; 85: 976-983
• 169 Libânio D, Pimentel-Nunes P, Afonso LP. et al. Long-term outcomes of gastric endoscopic submucosal dissection: focus on metachronous and non-curative resection management. GE Port J Gastroenterol 2017; 24: 31-39
• 170 Abe S, Oda I, Shimazu T. et al. Depth-predicting score for differentiated early gastric cancer. Gastric Cancer 2011; 14: 35-40
• 171 Choi J, Kim SG, Im JP. et al. Endoscopic prediction of tumor invasion depth in early gastric cancer. Gastrointest Endosc 2011; 73: 917-927
• 172 Toyoshima O, Yoshida S, Nishizawa T. et al. Enlarged folds on endoscopic gastritis as a predictor for submucosal invasion of gastric cancers. World J Gastrointest Endosc 2021; 13: 426-436
• 173 Tsujii Y, Hayashi Y, Ishihara R. et al. Diagnostic value of endoscopic ultrasonography for the depth of gastric cancer suspected of submucosal invasion: a multicenter prospective study. Surg Endosc 2023; 37: 3018-3028
• 174 Nagahama T, Yao K, Imamura K. et al. Diagnostic performance of conventional endoscopy in the identification of submucosal invasion by early gastric cancer: the "non-extension sign" as a simple diagnostic marker. Gastric Cancer 2017; 20: 304-313
• 175 Fairweather M, Jajoo K, Sainani N. et al. Accuracy of EUS and CT imaging in preoperative gastric cancer staging. J Surg Oncol 2015; 111: 1016-1020
• 176 Wang ZL, Li YL, Tang L. et al. Utility of the gastric window in computed tomography for differentiation of early gastric cancer (T1 stage) from muscularis involvement (T2 stage). Abdom Radiol (NY) 2021; 46: 1478-1486
• 177 Chung HW, Kim JH, Sung IK. et al. FDG PET/CT to predict the curability of endoscopic resection for early gastric cancer. J Cancer Res Clin Oncol 2019; 145: 759-764
• 178 Shi D, Xi XX. Factors affecting the accuracy of endoscopic ultrasonography in the diagnosis of early gastric cancer invasion depth: A meta-analysis. Gastroenterol Res Pract 2019; 2019: 8241381
• 179 Lee JY, Choi IJ, Kim CG. et al. Therapeutic decision-making using endoscopic ultrasonography in endoscopic treatment of early gastric cancer. Gut Liver 2016; 10: 42-50
• 180 Li X, Zhu M, Wang Y. et al. Diagnostic efficacy and decision-making role of preoperative endoscopic ultrasonography in early gastric cancer. Front Med (Lausanne) 2021; 8: 761295
• 181 Kuroki K, Oka S, Tanaka S. et al. Clinical significance of endoscopic ultrasonography in diagnosing invasion depth of early gastric cancer prior to endoscopic submucosal dissection. Gastric Cancer 2021; 24: 145-155
• 182 Kim SJ, Lim CH, Lee BI. Accuracy of endoscopic ultrasonography for determining the depth of invasion in early gastric cancer. Turk J Gastroenterol 2022; 33: 785-792
• 183 Hamada K, Itoh T, Kawaura K. et al. Examination of endoscopic ultrasonographic diagnosis for the depth of early gastric cancer. J Clin Med Res 2021; 13: 222-229
• 184 Zhao Y, Ren M, Jia A. et al. The factors influencing the accuracy of pre-operative endoscopic ultrasonography assessment in endoscopic treatments for gastrointestinal tumors. Cancer Med 2023; 12: 4321-4331
• 185 Gambitta P, Fontana P, Fanetti I. et al. Diagnostic accuracy of endoscopic ultrasonography in selecting patients for endoscopic submucosal dissection for early gastrointestinal neoplasms. J Clin Med 2023; 12: 2505
• 186 Chen H, Wang X, Shao S. et al. Value of EUS in determining infiltration depth of early carcinoma and associated precancerous lesions in the upper gastrointestinal tract. Endosc Ultrasound 2022; 11: 503-510
• 187 Libânio D, Dinis-Ribeiro M, Pimentel-Nunes P. et al. Predicting outcomes of gastric endoscopic submucosal dissection using a Bayesian approach: a step for individualized risk assessment. Endosc Int Open 2017; 5: E563-E72
• 188 Pimentel-Nunes P, Libanio D, Lage J. et al. A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions. Endoscopy 2016; 48: 723-730
• 189 Fang S, Fu Y, Du S. et al. The role of the endoscopic grading of gastric intestinal metaplasia in assessing gastric cancer risk: A systematic review and meta-analysis. Front Oncol 2022; 12: 1018248
• 190 Wei N, Zhou M, Lei S. et al. From part to whole, operative link on to endoscopic grading of gastric intestinal metaplasia, pathology to endoscopy: gastric intestinal metaplasia graded by endoscopy. Future Oncol 2022; 18: 2445-2454
• 191 Xiao S, Fan Y, Yin Z. et al. Endoscopic grading of gastric atrophy on risk assessment of gastric neoplasia: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021; 36: 55-63
• 192 Eriksson NK, Farkkila MA, Voutilainen ME. et al. The clinical value of taking routine biopsies from the incisura angularis during gastroscopy. Endoscopy 2005; 37: 532-536
• 193 Isajevs S, Liepniece-Karele I, Janciauskas D. et al. The effect of incisura angularis biopsy sampling on the assessment of gastritis stage. Eur J Gastroenterol Hepatol 2014; 26: 510-513
• 194 Kim YI, Kook MC, Cho SJ. et al. Effect of biopsy site on detection of gastric cancer high-risk groups by OLGA and OLGIM stages. Helicobacter 2017; 22
• 195 Marcos-Pinto R, Carneiro F, Dinis-Ribeiro M. et al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment Pharmacol Ther 2012; 35: 1451-1459
• 196 Lash JG, Genta RM. Adherence to the Sydney System guidelines increases the detection of Helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther 2013; 38: 424-431
• 197 Varbanova M, Wex T, Jechorek D. et al. Impact of the angulus biopsy for the detection of gastric preneoplastic conditions and gastric cancer risk assessment. J Clin Pathol 2016; 69: 19-25
• 198 Castro R, Esposito G. A single vial is enough in the absence of endoscopic suspected intestinal metaplasia – less is more!. Scand J Gastroenterol 2019; 54: 673-677
• 199 Zhang M, Liu S, Hu Y. et al. Biopsy strategies for endoscopic screening of pre-malignant gastric lesions. Sci Rep 2019; 9: 14909
• 200 Ferrari F, Ogata DC, Mello CAL. Role of incisura angularis biopsy in gastritis staging and risk assessment of gastric cancer. Arq Gastroenterol 2023; 60: 478-489
• 201 Khomeriki SG, Bordin DS, Khomeriki NM. et al. The impact of the angulus biopsy on the detection of staging and the grading of chronic gastritis. Diagnostics (Basel) 2023; 13: 2928
• 202 Yim K, Shin JH, Yoo J. Novel pathologic factors for risk stratification of gastric "indefinite for dysplasia" lesions. Gastroenterol Res Pract 2020; 2020: 9460681
• 203 Kwon MJ, Kang HS, Kim HT. et al. Treatment for gastric 'indefinite for neoplasm/dysplasia' lesions based on predictive factors. World J Gastroenterol 2019; 25: 469-484
• 204 Cho YS, Chung IK, Jung Y. et al. Risk stratification of patients with gastric lesions indefinite for dysplasia. Korean J Intern Med 2021; 36: 1074-1082
• 205 Yue H, Shan L, Bin L. The significance of OLGA and OLGIM staging systems in the risk assessment of gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2018; 21: 579-587
• 206 Wang JE, Kim SE, Lee BE. et al. The risk of diffuse-type gastric cancer following diagnosis with gastric precancerous lesions: a systematic review and meta-analysis. Cancer Causes Control 2022; 33: 183-191
• 207 Rugge M, Meggio A, Pennelli G. et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631-636
• 208 Satoh K, Osawa H, Yoshizawa M. et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008; 13: 225-229
• 209 Capelle LG, de Vries AC, Haringsma J. et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150-1158
• 210 Rugge M, de Boni M, Pennelli G. et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther 2010; 31: 1104-1111
• 211 Quach DT, Le HM, Nguyen OT. et al. The severity of endoscopic gastric atrophy could help to predict operative link on gastritis assessment gastritis stage. J Gastroenterol Hepatol 2011; 26: 281-285
• 212 Cho SJ, Choi IJ, Kook MC. et al. Staging of intestinal- and diffuse-type gastric cancers with the OLGA and OLGIM staging systems. Aliment Pharmacol Ther 2013; 38: 1292-1302
• 213 Kodama M, Murakami K, Okimoto T. et al. Histological characteristics of gastric mucosa prior to Helicobacter pylori eradication may predict gastric cancer. Scand J Gastroenterol 2013; 48: 1249-1256
• 214 Tsai YC, Hsiao WH, Yang HB. et al. The corpus-predominant gastritis index may serve as an early marker of Helicobacter pylori-infected patients at risk of gastric cancer. Aliment Pharmacol Ther 2013; 37: 969-978
• 215 Zhou Y, Li HY, Zhang JJ. et al. Operative link on gastritis assessment stage is an appropriate predictor of early gastric cancer. World J Gastroenterol 2016; 22: 3670-3678
• 216 Rugge M, Genta RM, Fassan M. et al. OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol 2018; 113: 1621-1628
• 217 Yun CY, Kim N, Lee J. et al. Usefulness of OLGA and OLGIM system not only for intestinal type but also for diffuse type of gastric cancer, and no interaction among the gastric cancer risk factors. Helicobacter 2018; 23: e12542
• 218 den Hollander WJ, Holster IL, den Hoed CM. et al. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. Gut 2019; 68: 585-593
• 219 Rugge M, Meggio A, Pravadelli C. et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut 2019; 68: 11-17
• 220 Chapelle N, Peron M, Queneherve L. et al. Long-term follow-up of gastric precancerous lesions in a low GC incidence area. Clin Transl Gastroenterol 2020; 11: e00237
• 221 Lee JWJ, Zhu F, Srivastava S. et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP). Gut 2022; 71: 854-863
• 222 Sun L, Jin X, Huang L. et al. Risk of progression in patients with chronic atrophic gastritis: A retrospective study. Front Oncol 2022; 12: 942091
• 223 Huang Y, Chen J, Guo Y. et al. Staging of operative link on gastritis assessment and operative link on gastric intestinal metaplasia systems for risk assessment of early gastric cancer: a case-control study. J Clin Pathol 2025; 78: 117-122
• 224 Na YS, Kim SG, Cho SJ. Risk assessment of metachronous gastric cancer development using OLGA and OLGIM systems after endoscopic submucosal dissection for early gastric cancer: a long-term follow-up study. Gastric Cancer 2023; 26: 298-306
• 225 Nakano T, Dohi O, Naito Y. et al. Efficacy and feasibility of magnifying blue laser imaging without biopsy confirmation for the diagnosis of the demarcation of gastric tumors: A randomized controlled study. Dig Dis 2021; 39: 156-164
• 226 Zhou J, Wu H, Fan C. et al. Comparison of the diagnostic efficacy of blue laser imaging with narrow band imaging for gastric cancer and precancerous lesions: a meta-analysis. Rev Esp Enferm Dig 2020; 112: 649-658
• 227 Dohi O, Yagi N, Naito Y. et al. Blue laser imaging-bright improves the real-time detection rate of early gastric cancer: a randomized controlled study. Gastrointest Endosc 2019; 89: 47-57
• 228 Yoshida N, Doyama H, Yano T. et al. Early gastric cancer detection in high-risk patients: a multicentre randomised controlled trial on the effect of second-generation narrow band imaging. Gut 2021; 70: 67-75
• 229 Nagahama T, Yao K, Uedo N. et al. Delineation of the extent of early gastric cancer by magnifying narrow-band imaging and chromoendoscopy: a multicenter randomized controlled trial. Endoscopy 2018; 50: 566-576
• 230 Yamamoto Y, Yoshida N, Yano T. et al. Assessment of outcomes from 1-year surveillance after detection of early gastric cancer among patients at high risk in Japan. JAMA Netw Open 2022; 5: e2227667
• 231 Akbari M, Kardeh B, Tabrizi R. et al. Incidence rate of gastric cancer adenocarcinoma in patients with gastric dysplasia: A systematic review and meta-analysis. J Clin Gastroenterol 2019; 53: 703-710
• 232 Ryu DG, Choi CW, Kang DH. et al. Pathologic outcomes of endoscopic submucosal dissection for gastric epithelial neoplasia. Medicine (Baltimore) 2018; 97: e11802
• 233 Goo JJ, Choi CW, Kang DH. et al. Risk factors associated with diagnostic discrepancy of gastric indefinite neoplasia: Who need en bloc resection?. Surg Endosc 2015; 29: 3761-3767
• 234 Yu CH, Jeon SW, Kim SK. et al. Endoscopic resection as a first therapy for gastric epithelial atypia: is it reasonable?. Dig Dis Sci 2014; 59: 3012-3020
• 235 Yang MJ, Shin SJ, Lee KS. et al. Non-neoplastic pathology results after endoscopic submucosal dissection for gastric epithelial dysplasia or early gastric cancer. Endoscopy 2015; 47: 598-604
• 236 Zhao J, Sun Z, Liang J. et al. Endoscopic submucosal dissection for early gastric cancer in elderly vs. non-elderly patients: A systematic review and meta-analysis. . Front Oncol 2021; 11: 718684
• 237 Waki K, Shichijo S, Uedo N. et al. Long-term outcomes after endoscopic resection for late-elderly patients with early gastric cancer. Gastrointest Endosc 2022; 95: 873-883
• 238 Kang S, Lee JH, Kim Y. et al. Comparison of endoscopic submucosal dissection and surgery for early gastric cancer that is not indicated for endoscopic resection in elderly patients. Surg Endosc 2023; 37: 4766-4773
• 239 Inokuchi Y, Ishida A, Hayashi K. et al. Feasibility of gastric endoscopic submucosal dissection in elderly patients aged ≥ 80 years. World J Gastrointest Endosc 2022; 14: 49-62
• 240 Yoshikawa T, Yamauchi A, Hamasaki R. et al. The safety and clinical validity of endoscopic submucosal dissection for early gastric cancer in patients aged more than 85 years. Cancers (Basel) 2022; 14: 3311
• 241 Yamada S, Dohi O, Harusato A. et al. Endoscopic submucosal dissection for early gastric cancer in patients aged 85 years old or older is associated with a good prognosis compared to conservative treatment without any invasive procedure. Digestion 2022; 103: 386-396
• 242 Watanabe K, Hikichi T, Nakamura J. et al. Endoscopic submucosal dissection for early gastric cancer in very elderly patients age 85 or older. Endosc Int Open 2017; 5: E17-E24
• 243 Natsagdorj E, Kim SG, Choi J. et al. Clinical outcomes of endoscopic submucosal dissection for early gastric cancer in patients with comorbidities. J Gastric Cancer 2021; 21: 258-267
• 244 Misawa N, Higurashi T, Tachikawa J. et al. Clinical impact of evaluation of frailty in endoscopic submucosal dissection for early gastric cancer in elderly patients. Geriatr Gerontol Int 2020; 20: 461-466
• 245 Ogata Y, Hatta W, Ohara Y. et al. Predictors of early and late mortality after the treatment for early gastric cancers. Dig Endosc 2022; 34: 816-825
• 246 Ito N, Funasaka K, Fujiyoshi T. et al. Scoring system for predicting the prognosis of elderly gastric cancer patients after endoscopic submucosal dissection. Dig Endosc 2023; 35: 67-76
• 247 Kim GH, Choi KD, Ko Y. et al. Impact of comorbidities, sarcopenia, and nutritional status on the long-term outcomes after endoscopic submucosal dissection for early gastric cancer in elderly patients aged ≥ 80 years. Cancers (Basel) 2021; 13: 3598
• 248 Toya Y, Endo M, Akasaka R. et al. Prognostic nutritional index is an independent prognostic factor for older patients aged ≥ 85 years treated by gastric endoscopic submucosal dissection. BMC Gastroenterol 2021; 21: 328
• 249 Hatta W, Toya Y, Shimada T. et al. Treatment strategy after noncurative endoscopic resection for early gastric cancers in patients aged ≥ 85 years: a multicenter retrospective study in a highly aged area of Japan. J Gastroenterol 2023; 58: 346-357
• 250 Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 2023; 26: 1-25
• 251 Kishida Y, Takizawa K, Kakushima N. et al. Endoscopic submucosal dissection versus surgery in elderly patients with early gastric cancer of relative indication for endoscopic resection. Dig Endosc 2022; 34: 497-507
• 252 Lim H, Jung HY, Park YS. et al. Discrepancy between endoscopic forceps biopsy and endoscopic resection in gastric epithelial neoplasia. Surg Endosc 2014; 28: 1256-1262
• 253 Yang L, Jin P, Wang X. et al. Risk factors associated with histological upgrade of gastric low-grade dysplasia on pretreatment biopsy. J Dig Dis 2018; 19: 596-604
• 254 Pimentel-Nunes P, Mourão F, Veloso N. et al. Long-term follow-up after endoscopic resection of gastric superficial neoplastic lesions in Portugal. Endoscopy 2014; 46: 933-940
• 255 Zhao G, Xue M, Hu Y. et al. How commonly is the diagnosis of gastric low grade dysplasia upgraded following endoscopic resection? A meta-analysis. . PLoS One 2015; 10: e0132699
• 256 Ngamruengphong S, Ferri L, Aihara H. et al. Efficacy of endoscopic submucosal dissection for superficial gastric neoplasia in a large cohort in North America. Clin Gastroenterol Hepatol 2021; 19: 1611-1619.e1
• 257 Shin GY, Park JY, Lee SH. et al. Tumor heterogeneity and carcinoma in resected specimens of gastric low-grade dysplasia: A retrospective single center study. PLoS One 2023; 18: e0280735
• 258 Jeon JW, Kim SJ, Jang JY. et al. Clinical outcomes of endoscopic resection for low-grade dysplasia and high-grade dysplasia on gastric pretreatment biopsy: Korea ESD study group. Gut Liver 2021; 15: 225-231
• 259 Xu X, Zheng G, Gao N. et al. Long-term outcomes and clinical safety of expanded indication early gastric cancer treated with endoscopic submucosal dissection versus surgical resection: A meta-analysis. BMJ Open 2022; 12: e055406
• 260 Sun F, Zhang S, Wang X. et al. Mixed histologic type is a risk factor for lymph node metastasis in submucosal invasive early gastric cancer. J Surg Res 2023; 282: 160-167
• 261 Benites-Goñi H, Palacios-Salas F, Carlin-Ronquillo A. et al. Endoscopic submucosal dissection versus surgery for patients with undifferentiated early gastric cancer. Rev Esp Enferm Dig 2023; 115: 3-9
• 262 Suzuki H, Ono H, Hirasawa T. et al. Long-term survival after endoscopic resection for gastric cancer: Real-world evidence from a multicenter prospective cohort. Clin Gastroenterol Hepatol 2023; 21: 307-318.e2
• 263 Meng ZW, Bishay K, Vaska M. et al. Endoscopic submucosal dissection versus surgery or endoscopic mucosal resection for metachronous early gastric cancer: A meta-analysis. J Gastrointest Surg 2023; 27: 2628-2639
• 264 Ortigão R, Figueirôa G, Frazzoni L. et al. Risk factors for gastric metachronous lesions after endoscopic or surgical resection: a systematic review and meta-analysis. Endoscopy 2022; 54: 892-901
• 265 Lee S, Kim SG, Cho SJ. Decision to perform additional surgery after non-curative endoscopic submucosal dissection for gastric cancer based on the risk of lymph node metastasis: A long-term follow-up study. Surg Endosc 2023; 37: 7738-7748
• 266 Morais R, Libanio D, Dinis Ribeiro M. et al. Predicting residual neoplasia after a non-curative gastric ESD: validation and modification of the eCura system in the Western setting: the W-eCura score. Gut 2023; 73: 105-117
• 267 Shimada S, Sawada N, Oae S. et al. Impact of non-curative endoscopic submucosal dissection on short- and long-term outcome of subsequent laparoscopic gastrectomy for pT1 gastric cancer. Surg Endosc 2022; 36: 3985-3993
• 268 Duan K, Li D, Shi D. et al. Risk factors and timing of additional surgery after noncurative ESD for early gastric cancer. Can J Gastroenterol Hepatol 2022; 2022: 3421078
• 269 Zhang L, Liu Y, You P. et al. Occurrence of gastric cancer in patients with atrophic gastritis during long-term follow-up. Scand J Gastroenterol 2018; 53: 843-848
• 270 Sui Z, Chen J, Li P. et al. Risk for gastric cancer in patients with gastric atrophy: a systematic review and meta-analysis. Transl Cancer Res 2020; 9: 1618-1624
• 271 Marcos P, Brito-Gonçalves G, Libânio D. et al. Endoscopic grading of gastric intestinal metaplasia on risk assessment for early gastric neoplasia: can we replace histology assessment also in the West?. Gut 2020; 69: 1762-1768
• 272 Dhingra R, Natov NS, Daaboul Y. et al. Increased risk of progression to gastric adenocarcinoma in patients with non-dysplastic gastric intestinal metaplasia versus a control population. Dig Dis Sci 2020; 65: 3316-3323
• 273 Dong EY, Giap AQ, Lustigova E. et al. Gastric cancer screening in first-degree relatives: A pilot study in a diverse integrated healthcare system. Clin Transl Gastroenterol 2022; 13: e00531
• 274 Sotelo S, Manterola C, Otzen T. et al. Prevalence of gastric preneoplastic lesions in first-degree relatives of patients with gastric cancer: a cross-sectional study. J Gastrointest Cancer 2023; 54: 513-519
• 275 Chen M, Liu XL, Zhu XJ. et al. Endoscopic grading of gastric atrophy and histological gastritis staging on risk assessment for early gastric cancer: A case-control study. J Dig Dis 2023; 24: 262-270
• 276 González CA, Pardo ML, Liso JM. et al. Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. Int J Cancer 2010; 127: 2654-2660
• 277 Rokkas T, Sechopoulos P, Pistiolas D. et al. Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis. Eur J Gastroenterol Hepatol 2010; 22: 1128-1133
• 278 Shichijo S, Hirata Y, Sakitani K. et al. Distribution of intestinal metaplasia as a predictor of gastric cancer development. J Gastroenterol Hepatol 2015; 30: 1260-1264
• 279 Song H, Ekheden IG, Zheng Z. et al. Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population. BMJ 2015; 351: h3867
• 280 Lee TY, Wang RC, Lee YC. et al. The incidence of gastric adenocarcinoma among patients with gastric intestinal metaplasia: A long-term cohort study. J Clin Gastroenterol 2016; 50: 532-537
• 281 Li D, Bautista MC, Jiang SF. et al. risks and predictors of gastric adenocarcinoma in patients with gastric intestinal metaplasia and dysplasia: A population-based study. Am J Gastroenterol 2016; 111: 1104-1113
• 282 Reddy KM, Chang JI, Shi JM. et al. Risk of gastric cancer among patients with intestinal metaplasia of the stomach in a US integrated health care system. Clin Gastroenterol Hepatol 2016; 14: 1420-1425
• 283 Nieminen AA, Kontto J, Puolakkainen P. et al. Comparison of operative link for gastritis assessment, operative link on gastric intestinal metaplasia assessment, and TAIM stagings among men with atrophic gastritis. World J Gastroenterol 2020; 26: 3447-3457
• 284 Piazuelo MB, Bravo LE, Mera RM. et al. The Colombian chemoprevention trial: 20-year follow-up of a cohort of patients with gastric precancerous lesions. Gastroenterology 2021; 160: 1106-1117.e3
• 285 Laszkowska M, Truong H, Faye AS. et al. Prevalence of extensive and limited gastric intestinal metaplasia and progression to dysplasia and gastric cancer. Dig Dis Sci 2022; 67: 3693-3701
• 286 Akbari M, Tabrizi R, Kardeh S. et al. Gastric cancer in patients with gastric atrophy and intestinal metaplasia: A systematic review and meta-analysis. PLoS One 2019; 14: e0219865
• 287 Choi AY, Strate LL, Fix MC. et al. Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U. S. population. Gastrointest Endosc 2018; 87: 1023-1028
• 288 Du S, Yang Y, Fang S. et al. Gastric cancer risk of intestinal metaplasia subtypes: A systematic review and meta-analysis of cohort studies. Clinical and translational gastroenterology 2021; 12: e00402
• 289 Wei N, Zhou M, Lei S. et al. A meta-analysis and systematic review on subtypes of gastric intestinal metaplasia and neoplasia risk. Cancer Cell Int 2021; 21: 173
• 290 Gawron AJ, Shah SC, Altayar O. et al. AGA technical review on gastric intestinal metaplasia-natural history and clinical outcomes. Gastroenterology 2020; 158: 705-731.e5
• 291 Shao L, Li P, Ye J. et al. Risk of gastric cancer among patients with gastric intestinal metaplasia. Int J Cancer 2018; 143: 1671-1677
• 292 Huang RJ, Ende AR, Singla A. et al. Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy. Gastrointest Endosc 2020; 91: 70-77.e1
• 293 Prakash P, Jain S, Trieu H. et al. Clinical epidemiology and outcomes of patients with gastric intestinal metaplasia in the Los Angeles County System. BMC Gastroenterol 2023; 23: 165
• 294 Nieuwenburg SAV, Mommersteeg MC, Eikenboom EL. et al. Factors associated with the progression of gastric intestinal metaplasia: a multicenter, prospective cohort study. Endosc Int Open 2021; 9: E297-E305
• 295 Usui Y, Taniyama Y, Endo M. et al. Helicobacter pylori, homologous-recombination genes, and gastric cancer. N Engl J Med 2023; 388: 1181-1190
• 296 Hwang YJ, Kim N, Lee HS. et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication – a prospective study for up to 10 years. Aliment Pharmacol Ther 2018; 47: 380-390
• 297 Kong YJ, Yi HG, Dai JC. et al. Histological changes of gastric mucosa after Helicobacter pylori eradication: a systematic review and meta-analysis. World J Gastroenterol 2014; 20: 5903-5911
• 298 Lahner E, Bordi C, Cattaruzza MS. et al. Long-term follow-up in atrophic body gastritis patients: atrophy and intestinal metaplasia are persistent lesions irrespective of Helicobacter pylori infection. Aliment Pharmacol Ther 2005; 22: 471-481
• 299 Wong BC, Lam SK, Wong WM. et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. Jama 2004; 291: 187-194
• 300 Esposito G, Pimentel-Nunes P, Angeletti S. et al. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. Endoscopy 2019; 51: 515-521
• 301 Yan L, Chen Y, Chen F. et al. Effect of Helicobacter pylori eradication on gastric cancer prevention: Updated report from a randomized controlled trial with 26.5 years of follow-up.. Gastroenterology 2022; 163: 154-162.e3
• 302 Li D, Jiang SF, Lei NY. et al. Effect of Helicobacter pylori eradication therapy on the incidence of noncardia gastric adenocarcinoma in a large diverse population in the United States. Gastroenterology 2023; 165: 391-401.e2
• 303 Choi IJ, Kook M-C, Kim Y-I. et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018; 378: 1085-1095
• 304 Suna N, Etik D, Öcal S. et al. The effect of helicobacter pylori eradication on atrophic gastritis and intestinal metaplasia: a retrospective single center research. Acta Gastroenterol Belg 2020; 83: 381-384
• 305 Zhu F, Zhang X, Li P. et al. Effect of Helicobacter pylori eradication on gastric precancerous lesions: A systematic review and meta-analysis. Helicobacter 2023; 28: e13013
• 306 Venerito M, Ford AC, Rokkas T. et al. Review: Prevention and management of gastric cancer. Helicobacter 2020; 25 (Suppl. 01) e12740
• 307 Moss SF, Shah SC, Tan MC. et al. Evolving concepts in Helicobacter pylori management. Gastroenterology 2024; 166: 267-283
• 308 Ford AC, Yuan Y, Moayyedi P. Long-term impact of Helicobacter pylori eradication therapy on gastric cancer incidence and mortality in healthy infected individuals: a meta-analysis beyond 10 years of follow-up. Gastroenterology 2022; 163: 754-756.e1
• 309 Ford AC, Yuan Y, Forman D. et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020; 7: CD005583
• 310 Khan MY, Aslam A, Mihali AB. et al. Effectiveness of Helicobacter pylori eradication in preventing metachronous gastric cancer and preneoplastic lesions. A systematic review and meta-analysis.. Eur J Gastroenterol Hepatol 2020; 32: 686-694
• 311 Kodama M, Okimoto T, Mizukami K. et al. Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study. J Gastroenterol Hepatol 2021; 36: 2210-2216
• 312 Gupta S, Li D, El Serag HB. et al. AGA Clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology 2020; 158: 693-702
• 313 Bae SE, Jung HY, Kang J. et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol 2014; 109: 60-67
• 314 Watari J, Tomita T, Tozawa K. et al. Preventing metachronous gastric cancer after the endoscopic resection of gastric epithelial neoplasia: roles of helicobacter pylori eradication and aspirin. Gut Liver 2020; 14: 281-290
• 315 Choi JM, Kim SG, Choi J. et al. Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc 2018; 88: 475-485.e2
• 316 Han SJ, Kim SG, Lim JH. et al. Long-term effects of Helicobacter pylori eradication on metachronous gastric cancer development. Gut Liver 2018; 12: 133-141
• 317 Choe Y, Park JM, Kim JS. et al. Factors influencing occurrence of metachronous gastric cancer after endoscopic resection: a systematic review and meta-analysis. Korean J Intern Med 2023; 38: 831-843
• 318 Schulz C, Schütte K, Koch N. et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut 2018; 67: 216-225
• 319 Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I. et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut 2018; 67: 226-236
• 320 Coker OO, Dai Z, Nie Y. et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut 2018; 67: 1024-1032
• 321 Gao JJ, Zhang Y, Gerhard M. et al. Association between gut microbiota and Helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer. Front Cell Infect Microbiol 2018; 8: 202
• 322 Park CH, Lee AR, Lee YR. et al. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter 2019; 24: e12547
• 323 Rajilic-Stojanovic M, Figueiredo C, Smet A. et al. Systematic review: gastric microbiota in health and disease. Aliment Pharmacol Ther 2020; 51: 582-602
• 324 Castaño-Rodríguez N, Goh KL, Fock KM. et al. Dysbiosis of the microbiome in gastric carcinogenesis. Scientific reports 2017; 7: 15957
• 325 Eun CS, Kim BK, Han DS. et al. Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods. Helicobacter 2014; 19: 407-416
• 326 Guo Y, Zhang Y, Gerhard M. et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut 2020; 69: 1598-1607
• 327 Engstrand L, Graham DY. Microbiome and gastric cancer. Dig Dis Sci 2020; 65: 865-873
• 328 Lofgren JL, Whary MT, Ge Z. et al. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 2011; 140: 210-220
• 329 Lertpiriyapong K, Whary MT, Muthupalani S. et al. Gastric colonisation with a restricted commensal microbiota replicates the promotion of neoplastic lesions by diverse intestinal microbiota in the Helicobacter pylori INS-GAS mouse model of gastric carcinogenesis. Gut 2014; 63: 54-63
• 330 Malfertheiner P, Megraud F, O'Morain CA. et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30
• 331 Hatta W, Koike T, Asonuma S. et al. Smoking history and severe atrophic gastritis assessed by pepsinogen are risk factors for the prevalence of synchronous gastric cancers in patients with gastric endoscopic submucosal dissection: a multicenter prospective cohort study. J Gastroenterol 2023; 58: 433-443
• 332 Ami R, Hatta W, Iijima K. et al. Factors associated with metachronous gastric cancer development after endoscopic submucosal dissection for early gastric cancer. J Clin Gastroenterol 2017; 51: 494-499
• 333 Abiko S, Shimizu Y, Ishikawa M. et al. Effects of activation of an alcohol metabolic gene, cigarette smoking, and alcohol intake on the incidence of metachronous gastric cancer in patients who underwent endoscopic resection for gastric cancer: A multicenter retrospective pilot study. JGH Open 2023; 7: 305-310
• 334 Brito-Gonçalves G, Libânio D, Marcos P. et al. Clinicopathologic characteristics of patients with gastric superficial neoplasia and risk factors for multiple lesions after endoscopic submucosal dissection in a western country. GE Port J Gastroenterol 2020; 27: 76-89
• 335 Nakamura M, Haruma K, Kamada T. et al. Cigarette smoking promotes atrophic gastritis in Helicobacter pylori-positive subjects. Dig Dis Sci 2002; 47: 675-681
• 336 Peleteiro B, Lunet N, Figueiredo C. et al. Smoking, Helicobacter pylori virulence, and type of intestinal metaplasia in Portuguese males. Cancer Epidemiol Biomarkers Prev 2007; 16: 322-326
• 337 Morais S, Rodrigues S, Amorim L. et al. Tobacco smoking and intestinal metaplasia: Systematic review and meta-analysis. Dig Liver Dis 2014; 46: 1031-1037
• 338 Lundell L, Vieth M, Gibson F. et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther 2015; 42: 649-663
• 339 Gao H, Li L, Geng K. et al. Use of proton pump inhibitors for the risk of gastric cancer. Medicine (Baltimore) 2022; 101: e32228
• 340 Ahn JS, Eom CS, Jeon CY. et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol 2013; 19: 2560-2568
• 341 Peng TR, Wu TW, Li CH. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Int J Clin Oncol 2023; 28: 99-109
• 342 Guo H, Zhang R, Zhang P. et al. Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis. Front Pharmacol 2023; 14: 1129948
• 343 Liu K, Wang YH, Wang J. et al. Meta-analysis of proton pump inhibitor use and the risk of developing gastric cancer or colorectal cancer. Anticancer Drugs 2023; 34: 971-978
• 344 Jiang K, Jiang X, Wen Y. et al. Relationship between long-term use of proton pump inhibitors and risk of gastric cancer: A systematic analysis. J Gastroenterol Hepatol 2019; 34: 1898-1905
• 345 Pan S, Thrift AP, Akhdar G. et al. Gastric cancer risk in patients with long-term use of proton pump inhibitors: A systematic review and meta-analysis of observational and interventional studies. Dig Dis Sci 2023; 68: 3732-3744
• 346 Piovani D, Tsantes AG, Schünemann HJ. et al. Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther 2023; 57: 653-665
• 347 Segna D, Brusselaers N, Glaus D. et al. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol 2021;
• 348 Poly TN, Lin MC, Syed-Abdul S. et al. Proton pump inhibitor use and risk of gastric cancer: current evidence from epidemiological studies and critical appraisal. Cancers (Basel) 2022; 14: 3052
• 349 Song HJ, Rhew K, Lee YJ. et al. Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis. Int J Clin Oncol 2021; 26: 34-50
• 350 Tran-Duy A, Spaetgens B, Hoes AW. et al. Use of proton pump inhibitors and risks of fundic gland polyps and gastric cancer: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1706-1719.e5
• 351 Zhang ML, Fan YX, Meng R. et al. Proton pump inhibitors and cancer risk: an umbrella review and meta-analysis of observational studies. Am J Clin Oncol 2022; 45: 475-485
• 352 Zheng Z, Lu Z, Song Y. Long-term proton pump inhibitors use and its association with premalignant gastric lesions: a systematic review and meta-analysis. Front Pharmacol 2023; 14: 1244400
• 353 Li Z, Wu C, Li L. et al. Effect of long-term proton pump inhibitor administration on gastric mucosal atrophy: A meta-analysis. Saudi J Gastroenterol 2017; 23: 222-228
• 354 Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev 2014; 2014: CD010623
• 355 Lv F, Wang J, Mao L. et al. Whether long-term use of proton pump inhibitor increases the risk of precancerous lesions in the stomach: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2023; 102: e35062
• 356 Oura H, Matsumura T, Kawasaki Y. et al. Long-term use of proton pump inhibitors does not affect ectopic and metachronous recurrence of gastric cancer after endoscopic treatment. Scand J Gastroenterol 2020; 55: 209-215
• 357 Seo SI, Park CH, Kim TJ. et al. Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer Med 2022; 11: 1217-1231
• 358 Wang L, Zhang R, Yu L. et al. Aspirin use and common cancer risk: a meta-analysis of cohort studies and randomized controlled trials. Front Oncol 2021; 11: 690219
• 359 Win TT, Aye SN, Lau Chui Fern J. et al. Aspirin and reducing risk of gastric cancer: systematic review and meta-analysis of the observational studies. J Gastrointestin Liver Dis 2020; 29: 191-198
• 360 Bosetti C, Santucci C, Gallus S. et al. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol 2020; 31: 558-568
• 361 Niikura R, Hirata Y, Hayakawa Y. et al. Effect of aspirin use on gastric cancer incidence and survival: A systematic review and meta-analysis. JGH Open 2020; 4: 117-125
• 362 Jung S, Park CH, Kim EH. et al. Preventing metachronous gastric lesions after endoscopic submucosal dissection through Helicobacter pylori eradication. J Gastroenterol 2015; 30: 75-81
• 363 Kim JE, Kim TJ, Lee H. et al. Aspirin use is not associated with the risk of metachronous gastric cancer in patients without helicobacter pylori infection. J Clin Med 2021; 11: 193
• 364 Ma Z, Wang W, Jin G. et al. Effect of statins on gastric cancer incidence: a meta-analysis of case control studies. J Cancer Res Ther 2014; 10: 859-865
• 365 Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1721-1730
• 366 Spence AD, Busby J, Hughes CM. et al. Statin use and survival in patients with gastric cancer in two independent population-based cohorts. Pharmacoepidemiol Drug Saf 2019; 28: 460-470
• 367 Su CH, Islam MM, Jia G. et al. Statins and the risk of gastric cancer: a systematic review and meta-analysis. J Clin Med 2022; 11: 7180
• 368 Wu XD, Zeng K, Xue FQ. et al. Statins are associated with reduced risk of gastric cancer: a meta-analysis. Eur J Clin Pharmacol 2013; 69: 1855-1860
• 369 Yuan M, Han S, Jia Y. et al. Statins are associated with improved survival of patients with gastric cancer: a systematic review and meta-analysis. Int J Clin Pract 2022; 2022: 4938539
• 370 Chen X, Li L, Liang Y. et al. Relationship of vitamin D intake, serum 25(OH) D, and solar ultraviolet-B radiation with the risk of gastric cancer: A meta-analysis. J Cancer Res Ther 2022; 18: 1417-1424
• 371 Chung H, Kim HJ, Jung HC. et al. Statins and metachronous recurrence after endoscopic resection of early gastric cancer: a nationwide Korean cohort study. Gastric Cancer 2020; 23: 659-666
• 372 Wang WH, Huang JQ, Zheng GF. et al. Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003; 95: 1784-1791
• 373 Tian W, Zhao Y, Liu S. et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 2010; 19: 288-298
• 374 Kong P, Wu R, Liu X. et al. The effects of anti-inflammatory drug treatment in gastric cancer prevention: an update of a meta-analysis. J Cancer 2016; 7: 2247-2257
• 375 MacArthur TA, Harmsen WS, Mandrekar J. et al. Association of common medications and the risk of early-onset gastric cancer: a population-based matched study. J Cancer Epidemiol 2021; 2021: 2670502
• 376 Sheu BS, Tsai YC, Wu CT. et al. Long-term celecoxib can prevent the progression of persistent gastric intestinal metaplasia after H. pylori eradication. Helicobacter 2013; 18: 117-123
• 377 Wong BC, Zhang L, Ma JL. et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012; 61: 812-818
• 378 Franciosi M, Lucisano G, Lapice E. et al. Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One 2013; 8: e71583
• 379 Li P, Zhang C, Gao P. et al. Metformin use and its effect on gastric cancer in patients with type 2 diabetes: A systematic review of observational studies. Oncol Lett 2018; 15: 1191-1199
• 380 Shuai Y, Li C, Zhou X. The effect of metformin on gastric cancer in patients with type 2 diabetes: a systematic review and meta-analysis. Clin Transl Oncol 2020; 22: 1580-1590
• 381 Kong P, Cai Q, Geng Q. et al. Vitamin intake reduce the risk of gastric cancer: meta-analysis and systematic review of randomized and observational studies. PLoS One 2014; 9: e116060
• 382 Zhang T, Yi X, Li J. et al. Vitamin E intake and multiple health outcomes: an umbrella review. Front Public Health 2023; 11: 1035674
• 383 Wang SM, Taylor PR, Fan JH. et al. Effects of nutrition intervention on total and cancer mortality: 25-year post-trial follow-up of the 5.25-year Linxian Nutrition Intervention Trial.. J Natl Cancer Inst 2018; 110: 1229-1238
• 384 Wang JB, Abnet CC, Fan JH. et al. The randomized Linxian Dysplasia Nutrition Intervention Trial after 26 years of follow-up: no effect of multivitamin supplementation on mortality. JAMA Intern Med 2013; 173: 1259-1261
• 385 Su XQ, Yin ZY, Jin QY. et al. Allium vegetable intake associated with the risk of incident gastric cancer: a continuous follow-up study of a randomized intervention trial. Am J Clin Nutr 2023; 117: 22-32
• 386 Guo Y, Li ZX, Zhang JY. et al. Association between lifestyle factors, vitamin and garlic supplementation, and gastric cancer outcomes: a secondary analysis of a randomized clinical trial. JAMA Netw Open 2020; 3: e206628
• 387 Li WQ, Zhang JY, Ma JL. et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ 2019; 366: l5016
• 388 Ma JL, Zhang L, Brown LM. et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012; 104: 488-492
• 389 Dawsey SP, Hollenbeck A, Schatzkin A. et al. A prospective study of vitamin and mineral supplement use and the risk of upper gastrointestinal cancers. PLoS One 2014; 9: e88774
• 390 Khayatzadeh S, Feizi A, Saneei P. et al. Vitamin D intake, serum vitamin D levels, and risk of gastric cancer: A systematic review and meta-analysis. J Res Med Sci 2015; 20: 790-796
• 391 Kanno K, Akutsu T, Ohdaira H. et al. Effect of vitamin D supplements on relapse or death in a p53-immunoreactive subgroup with digestive tract cancer: post hoc analysis of the AMATERASU randomized clinical trial. JAMA Netw Open 2023; 6: e2328886
• 392 Urashima M, Ohdaira H, Akutsu T. et al. Effect of vitamin D supplementation on relapse-free survival among patients with digestive tract cancers: the AMATERASU randomized clinical trial. Jama 2019; 321: 1361-1369
• 393 Vinceti M, Filippini T, Del Giovane C. et al. Selenium for preventing cancer. Cochrane Database Syst Rev 2018; 1: CD005195
• 394 Setia N, Clark JW, Duda DG. et al. Familial gastric cancers. Oncologist 2015; 20: 1365-1377
• 395 Ortigão R, Brito M, Pinto C. et al. Risk factors for gastric cancer in patients with Lynch syndrome. Eur J Gastroenterol Hepatol 2022; 34: 912-918
• 396 Kim J, Braun D, Ukaegbu C. et al. Clinical factors associated with gastric cancer in individuals with Lynch syndrome. Clin Gastroenterol Hepatol 2020; 18: 830-837.e1
• 397 Chautard R, Malka D, Samaha E. et al. Upper gastrointestinal lesions during endoscopy surveillance in patients with Lynch syndrome: a multicentre cohort study. Cancers (Basel) 2021; 13: 1657
• 398 Nakano K, Kawachi H, Chino A. et al. Phenotypic variations of gastric neoplasms in familial adenomatous polyposis are associated with endoscopic status of atrophic gastritis. Dig Endosc 2020; 32: 547-556
• 399 Lenti MV, Rugge M, Lahner E. et al. Autoimmune gastritis. Nat Rev Dis Primers 2020; 6: 56
• 400 Esposito G, Dottori L, Pivetta G. et al. Pernicious anemia: The hematological presentation of a multifaceted disorder caused by cobalamin deficiency. Nutrients 2022; 14: 1672
• 401 Weise F, Vieth M, Reinhold D. et al. Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research. United European Gastroenterol J 2020; 8: 175-184
• 402 Hu H, Li R, Shao L. et al. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis: a retrospective study in a single center. Scand J Gastroenterol 2022; 57: 1296-1303
• 403 Mahmud N, Stashek K, Katona BW. et al. The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance. Ann Gastroenterol 2019; 32: 67-72
• 404 Chen C, Yang Y, Li P. et al. Incidence of gastric neoplasms arising from autoimmune metaplastic atrophic gastritis: a systematic review and case reports. J Clin Med 2023; 12: 1062
• 405 Esposito G, Dilaghi E, Cazzato M. et al. Endoscopic surveillance at 3 years after diagnosis, according to European guidelines, seems safe in patients with atrophic gastritis in a low-risk region. Dig Liver Dis 2021; 53: 467-473
• 406 Kralickova P, Milota T, Litzman J. et al. CVID-associated tumors: Czech nationwide study focused on epidemiology, immunology, and genetic background in a cohort of patients with CVID. Front Immunol 2018; 9: 3135
• 407 Bruns L, Panagiota V, von Hardenberg S. et al. Common variable immunodeficiency-associated cancers: the role of clinical phenotypes, immunological and genetic factors. Front Immunol 2022; 13: 742530
• 408 Mayor PC, Eng KH, Singel KL. et al. Cancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol 2018; 141: 1028-1035
• 409 Vajdic CM, Mao L, van Leeuwen MT. et al. Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?. Blood 2010; 116: 1228-1234
• 410 Quinti I, Soresina A, Spadaro G. et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007; 27: 308-316
• 411 Gullo I, Costa C, Silva SL. et al. The dysfunctional immune system in common variable immunodeficiency increases the susceptibility to gastric cancer. Cells 2020; 9: 1498
• 412 Krein P, Yogolare GG, Pereira MA. et al. Common variable immunodeficiency: an important but little-known risk factor for gastric cancer. Rev Col Bras Cir 2021; 48: e20213133
• 413 Pulvirenti F, Pecoraro A, Cinetto F. et al. Gastric cancer is the leading cause of death in Italian adult patients with common variable immunodeficiency. Front Immunol 2018; 9: 2546
• 414 Dhalla F, da Silva SP, Lucas M. et al. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol 2011; 165: 1-7
• 415 Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34-48
• 416 Chen Y, You Y, Li J. et al. Endoscopic and histopathological hints on infections in patients of common variable immunodeficiency disorder with gastrointestinal symptoms. BMC Gastroenterol 2023; 23: 413
• 417 Chapel H, Lucas M, Lee M. et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008; 112: 277-286
• 418 Song M, Latorre G, Ivanovic-Zuvic D. et al. Autoimmune diseases and gastric cancer risk: a systematic review and meta-analysis. Cancer Res Treat 2019; 51: 841-850
• 419 Bernatsky S, Ramsey-Goldman R, Urowitz MB. et al. Cancer risk in a large inception systemic lupus erythematosus cohort: effects of demographic characteristics, smoking, and medications. Arthritis Care Res (Hoboken) 2021; 73: 1789-1795
• 420 Hsu CY, Lin MS, Su YJ. et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford) 2017; 56: 620-628
• 421 Zhang Y, Lin J, You Z. et al. Cancer risks in rheumatoid arthritis patients who received immunosuppressive therapies: Will immunosuppressants work?. Front Immunol 2022; 13: 1050876
• 422 Nissen LH, Assendorp EL, van der Post RS. et al. Impaired gastric cancer survival in patients with inflammatory bowel disease. J Gastrointestin Liver Dis 2016; 25: 431-440
• 423 Turshudzhyan A. Post-renal transplant malignancies: Opportunities for prevention and early screening. Cancer Treat Res Commun 2021; 26: 100283
• 424 Lee IS, Kim TH, Kim YH. et al. Clinical significance of gastric cancer surveillance in renal transplant recipients. World J Surg 2012; 36: 1806-1810
• 425 Végso G, Tóth M, Hídvégi M. et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res 2007; 13: 63-69
• 426 Hibberd AD, Trevillian PR, Wlodarczyk JH. et al. Effect of immunosuppression for primary renal disease on the risk of cancer in subsequent renal transplantation: a population-based retrospective cohort study. Transplantation 2013; 95: 122-127
• 427 Rinaldi M, Pellegrini C, D'Armini AM. et al. Neoplastic disease after heart transplantation: single center experience. Eur J Cardiothorac Surg 2001; 19: 696-701
• 428 Ondrus D, Pribylincová V, Breza J. et al. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 1999; 31: 417-422
• 429 Buell JF, Husted T, Hanaway MJ. et al. Incidental diagnosis of gastric cancer in transplant recipients improves patient survival. Surgery 2002; 132: 754 758; discussion 8-60
• 430 Grulich AE, van Leeuwen MT, Falster MO. et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67
• 431 Palmela C, Fonseca C, Faria R. et al. Increased risk for metachronous gastric adenocarcinoma following gastric MALT lymphoma – a US population-based study. United European Gastroenterol J 2017; 5: 473-478
• 432 Capelle LG, de Vries AC, Looman CW. et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer 2008; 44: 2470-2476
• 433 Feng Y, Duan TJ, Huang Q. et al. The clinicopathological characteristics of gastric cancer and precancerous conditions in gastric DLBCL and MALT lymphoma patients: a multi-center retrospective study. Ann Med 2023; 55: 2193423
• 434 Wündisch T, Dieckhoff P, Greene B. et al. Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years. Gastroenterology 2012; 143: 936 942; quiz e13-14
• 435 Parra-Medina R, Rocha F, Castañeda-González JP. et al. Synchronous or collision solid neoplasms and lymphomas: A systematic review of 308 case reports. Medicine (Baltimore) 2022; 101: e28988
• 436 Capelle L, den Hoed C, de Vries A. et al. Premalignant gastric lesions in patients with gastric mucosa-associated lymphoid tissue lymphoma and metachronous gastric adenocarcinoma: A case-control study. Eur J Gastroenterol Hepatol 2012; 24: 42-47
• 437 Matysiak-Budnik T, Jamet P, Ruskoné-Fourmestraux A. et al. Gastric MALT lymphoma in a population-based study in France: clinical features, treatments and survival. Aliment Pharmacol Ther 2019; 50: 654-663
• 438 Rentien AL, Lévy M, Copie-Bergman C. et al. Long-term course of precancerous lesions arising in patients with gastric MALT lymphoma. Dig Liver Dis 2018; 50: 181-188
• 439 Zullo A, Rago A, Felici S. et al. Onset and progression of precancerous lesions on gastric mucosa of patients treated for gastric lymphoma. J Gastrointestin Liver Dis 2020; 29: 27-31
• 440 Lamarque D, Levy M, Chaumette MT. et al. Frequent and rapid progression of atrophy and intestinal metaplasia in gastric mucosa of patients with MALT lymphoma. Am J Gastroenterol 2006; 101: 1886-1893
• 441 Copie-Bergman C, Locher C, Levy M. et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?. Ann Oncol 2005; 16: 1232-1236
• 442 Capitani N, Codolo G, Vallese F. et al. The lipoprotein HP1454 of Helicobacter pylori regulates T-cell response by shaping T-cell receptor signalling. Cell Microbiol 2019; 21: e13006
• 443 Della Bella C, Soluri MF, Puccio S. et al. The Helicobacter pylori CagY protein drives gastric Th1 and Th17 inflammation and B cell proliferation in gastric MALT lymphoma. Int J Mol Sci 2021; 22: 9459
• 444 Jacob J, Millien V, Berger S. et al. Improving adherence to clinical practice guidelines for managing gastric intestinal metaplasia among gastroenterologists at a US academic institution. J Clin Gastroenterol 2024; 58: 432-439
• 445 Zagari RM, Frazzoni L, Fuccio L. et al. Corrigendum: Adherence to European Society of Gastrointestinal Endoscopy quality performance measures for upper and lower gastrointestinal endoscopy: a nationwide survey from the Italian Society of Digestive Endoscopy. Front Med (Lausanne) 2024; 11: 1406746
• 446 Lahner E, Zullo A, Hassan C. et al. Detection of gastric precancerous conditions in daily clinical practice: a nationwide survey. Helicobacter 2014; 19: 417-424
• 447 Honing J, Keith Tan W, Dieninyte E. et al. Adequacy of endoscopic recognition and surveillance of gastric intestinal metaplasia and atrophic gastritis: A multicentre retrospective study in low incidence countries. PLoS One 2023; 18: e0287587
• 448 Hassan C, Ponchon T, Bisschops R. et al. European Society of Gastrointestinal Endoscopy (ESGE) Publications Policy – Update 2020. Endoscopy 2020; 52: 123-126